US-based healthcare company Solventum has unveiled the V.A.C. Peel and Place Dressing, a new integrated dressing and drape that simplifies application and extends wear time.
V.A.C. Peel and Place Dressing can be applied in under two minutes and is designed to be worn by patients for up to seven days.
Solventum, spun out of 3M in April 2024, has designed the new dressing to replace traditional dressings for negative pressure wound therapy.
The new V.A.C. Peel and Place Dressing represents the latest advancement in V.A.C. Therapy.
Its all-in-one dressing and drape design streamlines application, cutting down on both the time and training needed for dressing changes.
Additionally, the dressing includes a built-in perforated, non-adherent layer that minimises tissue ingrowth and makes removal more comfortable for patients.
Solventum medical surgical executive vice president and group president Chris Barry said: “Solventum is committed to overcoming clinical challenges and improving access to care so that more patients may benefit from V.A.C. Therapy, one of the most studied and effective advanced wound treatments available today.
“We are proud to be a pioneering leader in wound care, and we will continue our legacy of innovation by empowering and equipping healthcare providers with the tools they need to deliver better, smarter, and safer treatments to their patients.”
The V.A.C. Peel and Place Dressing is designed for a wide range of wounds up to 6cm deep, including chronic, acute, traumatic, subacute, and dehisced wounds.
It is also effective for partial thickness burns, ulcers, flaps, and grafts, the company said.
The dressing has been shown to cut therapy application time by 61% and reduce hospital costs by 41% due to fewer dressing changes.
Additionally, it can decrease the number of weekly home nursing visits by 67%.
The V.A.C. Peel and Place Dressing expands the applicability of V.A.C. Therapy, making it suitable for a broader range of patients in both acute and post-acute care settings.
The dressing is now available in the US and Canada, with additional global regulatory submissions and approvals in progress.
